🔎 Trials Near Me

Utama › Leukemia Limfositik Kronik › Georgia › Atlanta

Kajian klinikal Leukemia Limfositik Kronik di Atlanta, GA

11 kajian untuk Leukemia Limfositik Kronik sedang mencari peserta di lokasi dalam dan sekitar Atlanta (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.

Teks kajian rasmi (Bahasa Inggeris)

Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
  • Atlanta VA Medical Center, Decatur · 6 mi jauh
Umur 40 hingga 75 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT05334069

A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

Mengambil pesertaFasa 3
  • Emory University Winship Cancer Institute, Atlanta
  • Northside Cancer Center, Atlanta
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT06846671

Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

Mengambil pesertaFasa 1
  • Winship Cancer Institute Emory University, Atlanta
  • Northside Hospital Cancer Institute, Atlanta
Umur 18 ke atas · Semua jantina · Dikemas kini 8 Sep 2026 · NCT03666000

A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant

Mengambil pesertaFasa 1Sukarelawan sihat dialu-alukan
  • Northside Hospital, Atlanta
Umur 18 hingga 75 · Semua jantina · Dikemas kini 28 Jul 2026 · NCT07020533

Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma

Mengambil pesertaKajian pemerhatian
  • Emory University Hospital Midtown, Atlanta
  • Emory University Hospital/Winship Cancer Institute, Atlanta
Umur 18 ke atas · Semua jantina · Dikemas kini 6 Jul 2026 · NCT03501576

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

Mengambil pesertaFasa 1
  • Winship Cancer Institute of Emory University, Atlanta
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Jul 2026 · NCT05131022

CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant

Mengambil pesertaFasa 2Sukarelawan sihat dialu-alukan
  • Northside Hospital, Atlanta
Umur 18 hingga 75 · Semua jantina · Dikemas kini 10 Mac 2026 · NCT06059391

A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

Mengambil pesertaFasa 4
  • The Emory Clinic, Atlanta
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Mac 2026 · NCT06876662

A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

Mengambil pesertaFasa 4
  • The Emory Clinic, Atlanta
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Mac 2026 · NCT06876649

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)

Mengambil pesertaFasa 2
  • Winship Cancer Institute of Emory University /ID# 230643, Atlanta
Umur 18 ke atas · Semua jantina · Dikemas kini 9 Feb 2026 · NCT04895436

Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation

Mengambil pesertaFasa 2
  • Winship Cancer Institute at Emory University, Atlanta
Umur 18 ke atas · Semua jantina · Dikemas kini 7 Jan 2026 · NCT06043674

Kajian Leukemia Limfositik Kronik di bandar lain

Kajian lain di Atlanta

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.